Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Helena, Genberg"'
Publikováno v:
Transplantation. 106:S436-S436
Autor:
Felicia Kjaernet, Anna Bjerre, Zivile Bekassy, Amir Sedigh, Helle Thiesson, Hjördis Thorsteinsdottir, Anna Varberg Reisaeter, Susanne Westphal, Anders Åsberg, Helena Genberg
Publikováno v:
Transplantation. 106:S29-S29
Autor:
Helena Genberg, Felicia Kjaernet, Anna Bjerre, Zivile Bekassy, Amir Sedigh, Helle Thiesson, Hjördis Thorsteinsdottir, Anna Varberg Reisaeter, Susanne Westphal, Anders Åsberg
Publikováno v:
Transplantation. 106:S30-S30
Autor:
Johan Nordström, John Tyler Sandberg, Helena Genberg, Torbjörn Lundgren, Ulf Fränneby, Lars Wennberg
Publikováno v:
Transplantation. 104:S392-S393
Autor:
Anders, Svensson-Marcial, Helena, Genberg, Katharina, Brehmer, Raquel, Themudo, Torkel, Brismar B
Publikováno v:
Acta Radiologica Open; Sep2021, Vol. 10 Issue 9, p1-9, 9p
Publikováno v:
Nephrology Dialysis Transplantation. 26:2394-2400
Background. As antigen-specific immunoadsorption (IA) using the Glycosorb-ABO columns is becoming increasingly popular in ABO-incompatible (ABOi) transplantation, in this study, we retrospectively investigated the efficacy of Glycosorb-ABO IA in vivo
Publikováno v:
Transfusion and Apheresis Science. 43:231-235
As the demand for kidney transplantation is constantly growing methods to expand the donor pool have become increasingly important. ABO-incompatibility has hitherto been regarded as an absolute contraindication to living donor donation. However, as A
Autor:
Jonas Wadström, Markus Gäbel, Gunnar Tydén, Persson Nh, Jan Tollemar, Lars Mjörnstedt, Henrik Ekberg, Helena Genberg, Gunnar Tufveson
Publikováno v:
Transplantation. 87:1325-1329
We performed a prospective, double blind, randomized, placebo-controlled multicenter study on the efficacy and safety of rituximab as induction therapy, together with tacrolimus, mycophenolate mofetil, and steroids. The primary endpoint was defined a
Publikováno v:
Transplantation. 84:S44-S47
ABO-incompatible (ABOi) kidney transplantation has gained a renewed interest during the past years. In 2001, a protocol for ABOi kidney transplantation based on antigen-specific immunoadsorption and rituximab was introduced at our center. In this stu
Publikováno v:
American Journal of Transplantation. 6:2418-2428
The anti-CD20 antibody rituximab has recently gained interest as a B-cell depleting agent in renal transplantation. However, little is known about the pharmacodynamics of rituximab in renal transplant recipients. We have therefore studied the effect